Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.